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SUMMARY
ES-62 is a glycoprotein secreted by the filarial nematode
Acanthocheilonema viteae that protects against ovalbumin
(OVA)-induced airway hyper-responsiveness in mice by vir-
tue of covalently attached anti-inflammatory phosphoryl-
choline (PC) residues. We have recently generated a library
of small molecule analogues (SMAs) of ES-62 based
around its active PC moiety as a starting point in novel drug
development for asthma and identified two compounds –
termed 11a and 12b – that mirror ES-62’s protective effects.
In this study, we have moved away from OVA, a model
allergen, to test the SMAs against two clinically relevant
allergens – house dust mite (HDM) and cockroach allergen
(CR) extract. We show that both SMAs offer some protec-
tion against development of lung allergic responses to CR,
in particular reducing eosinophil infiltration, whereas only
SMA 12b is effective in protecting against eosinophil-depen-
dent HDM-induced allergy. These data therefore suggest
that helminth molecule-induced protection against model
allergens may not necessarily translate to clinically relevant
allergens. Nevertheless, in this study, we have managed to
demonstrate that it is possible to produce synthetic drug-like
molecules based on a parasitic worm product that show ther-
apeutic potential with respect to asthma resulting from
known triggers in humans.
Keywords allergen, asthma, ES-62, parasitic worm,
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INTRODUCTION
During the past decade, there has been increasing interest in
the idea that parasitic worms could be employed as novel
treatments to control allergic diseases such as asthma.
Although the idea originally arose from observations on
humans, the most convincing supportive data come from
studies with mouse models. Thus, infection with a wide
range of different nematode and trematode species has been
shown to protect mice against allergic lung disease
(reviewed in (1–3)). Furthermore, successful protection has
also been obtained when employing individual defined
parasitic worm products (reviewed in (1, 4)). One of
these defined products is ES-62, a phosphorylcholine (PC)-
containing glycoprotein secreted by Acanthocheilonema
viteae, which was shown to protect against disease develop-
ment in a prophylactic version of the ovalbumin-induced
airway hypersensitivity model (5, 6). Furthermore, drug-like
small molecule analogues (SMAs) based around ES-62’s
active PC moiety were found to be protective in this model
and also when applied therapeutically (7). However, consid-
ering ovalbumin is a protein used to model physiologically
relevant allergens, we have investigated whether these SMAs
are also protective when administered to mice given aller-
gens to which humans are naturally exposed, namely house
dust mite (HDM) and cockroach (CR) extract.
MATERIALS AND METHODS
Mice
Six- to eight-week-old C57BL/6 or BALB/c female mice were
obtained from Harlan Olac (UK) or the Biological Proce-
dures Unit (BPU), University of Strathclyde, UK. All animals
were maintained in the BPU at the University of Strathclyde
and housed in a pathogen-free environment. All procedures
were conducted in accordance with Home Office, UK animal
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guidelines (project licence number PPL60/4300) and with the
approval of the local university ethical committees.
HDM and CR extract models of allergic inflammation
Allergic inflammation was induced as previously described
(8, 9). Briefly, mice were anaesthetized with isoflurane prior
to intranasal (i.n.) administration of HDM (Der-
matophagoides pteronyssinus) or CR (Blattella germanica)
extract (Greer Laboratories, Lenoir, NC, USA), in sterile
PBS to induce sensitization. For HDM-induced allergic dis-
ease, mice were sensitized with 1 lg of HDM and challenged
on days 7–11 by i.n. treatment with 10 lg doses of HDM
extracts and the experiment was terminated on Day 14. For
CR-induced allergic disease, mice were sensitized with 50 lg
of CRon days 0–4 and then challenged with 50 lg of CRon
days 10–13 with termination of the model at Day 15. Control
mice received 25 lL of PBS. The models are summarized in
Figure S1. Endotoxin-free SMA 11a and SMA 12b were pre-
pared as described previously (10), and their structures can
be seen in Figure 1a. Animals were anaesthetized using
isoflurane andwere treatedwith SMA 11a and SMA 12b (10,
1 or 01 lg/dose) either i.n. 1 h prior to HDM administra-
tion or subcutaneously (s.c) following CR administration
where indicated. Disease-positive control mice received vec-
tor treatment in place of SMAs, and untreated control mice
received no SMA or HDM/CR. Serum, bronchoalveolar
lavage (BALF), draining lymph nodes (DLNs) and lungs
were removed, and ex vivo qRT-PCR, ELISA, differential
cell counts and flow cytometric analysis performed, as
described previously (5–7). Flow cytometric analysis of cell
populations utilized the following antibodies and fluo-
rochromes: anti-CD3e/PerCP, anti-Ly6C/FITC, anti-Ly6G/
APC, anti-CD11c/PE-Cy7 (all BioLegend, San Diego, CA,
USA), anti-CD19/APC-Cy7, anti-SiglecF/PE (BD Bio-
science, San Diego, CA, USA) and anti-F4/80/PE (eBio-
science, SanDiego, CA, USA).
Lung histopathology
The tissue morphology was preserved by embedding lungs in
10% formalin solution for 24 h. Lungs were then embedded
in Tissue-TekO.C.T.TM compound in Cryomolds and stored
at 70°C until further analyses. Tissue sections (7 lm) were
cut using a cryostat (Thermo Fisher, Renfrew, UK) and left
to air-dry for 24 h before haematoxylin and eosin (H&E)
and periodic acid-Schiff (PAS) staining were performed.
Quantitative real time PCR (qRT-PCR)
qRT-PCR was undertaken as described previously (6) and
using instructions provided in assay kits by Thermo
Fisher. Briefly, the upper lobe from the right lung of the
mouse was homogenized and used to extract RNA using
an RNeasy Plus Mini Kit (Qiagen, Manchester, UK). The
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Paisley, UK) was used to reverse transcribe
the obtained RNA, and the primers for IL-4 (Mm004452
59_m1), IL-5 (Mm00439646_m1), IL-13 (Mm004342
04_m1), IL-17 (Mm00439619_m1), IFN-c (Mm011681
34_m1), IL-1b (Mm00434228_m1), Hmox (Mm00516005_
m1) and GAPDH (Mm99999915_g1) were used to analyse
transcript levels. All samples were examined in duplicate,
and data were analysed by STEPONEPLUSTM software v 2.3
(Applied Biosystems, Paisley, UK) using the comparative
CT (DDCT) with values for samples being normalized to
the reference reporter GAPDH.
Detection of HDM/CR-specific IgE and IgG1
ELISA 96-well plates were coated with HDM or CR (2 lg/
mL in PBS) overnight at 4°C and were then washed and
blocked with 4% BSA/PBS (Sigma, Poole, Dorset, UK) for
1 h at 37°C. Serum was initially diluted 1/50 and then seri-
ally threefold 8 times prior to incubation in allergen-coated
plates at 37°C for 1 h. Horseradish peroxidase (HRP)-con-
jugated anti-IgE (anti-mouse IgE-HRP – 1 : 1000) and anti-
IgG1 (anti-mouse IgG1-HRP – 1 : 10 000) (antibodies
from Southern Biotech, Birmingham, AL, USA) were then
added and left for a further hour at 37°C to detect the
presence of HDM/CR-specific antibodies. Samples were
developed by addition of KPL SureBlue, TMB microwell
peroxidase substrate and reactions terminated by stop solu-
tion, 2N H2SO4. The final reactions were measured at
405 nm by employing an ELISA microplate reader.
Lymphocyte restimulation assay
Single cell suspensions of lung mediastinal lymph nodes
(3 9 105 cells) were incubated with medium alone or CR
(50 lg) for 72 h at 37°C. Cells were then pelleted at
400 9 g, and supernatants collected for cytokine analysis.
ELISAs were used to detect the concentration of IL-4 and
IFN-c according to the suppliers’ recommendations (BD
Bioscience). Samples were developed using KPL SureBlue,
TMB microwell peroxidase substrate and terminated by
stop solution; 2N H2SO4 with the final reactions being
measured at 405 nm using an ELISA microplate reader.
Statistics
Data were transformed and analysed by one-way ANOVA
using Bonferroni’s (parametric) or Dunn’s (nonparametric)
post hoc tests.
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Figure 1 SMA 12b decreases total cell counts and influx of eosinophils into the lungs of mice undergoing HDM-induced airway
inflammation. C57BL/6 mice undergoing HDM-induced airway inflammation were treated with SMA 11a or 12b 1 h before administering
HDM extracts throughout the model. The numbers after each SMA refer to the quantity of lg of SMA per injection. (a) structures of
SMAs 11a and 12b. (b) total cell count in BALF collected at sacrifice. Influx of eosinophils and macrophages is shown as both total
number of cells (c, e) and their proportion (d, f) in BALF, as determined by differential cell counts. Data are combined from 5 independent
experiments. Symbols on each graph are representative of individual mice in the indicated groups and where *P < 005 and **P < 001 for
12b-1-versus HDM (none) mice and ###P < 0001 for control vs. HDM mice.
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RESULTS
Effect of SMAs on cellular infiltration of the lungs in
response to HDM extract
Two SMAs previously shown to be effective in preventing
OVA-induced inflammation in the lungs (7) were examined
for their effects on cellular infiltration of the lungs in the
HDM model.
To determine the optimum concentration of SMA to be
employed, mice undergoing HDM-induced airway hyper-
responsiveness were administered 11a or 12b, 1 h prior to
HDM sensitization and at each challenge, at different con-
centrations – either 01 lg, 1 lg or 10 lg per injection –
throughout the model (Figure S1). A control group
(‘none’) received the DMSO vehicle instead of SMA. Mice
were culled on Day 14, and bronchoalveolar lavage fluid
(BALF) was collected for total and differential cell count
analysis. SMA 11a did not show protective effects at any
of the three concentrations employed (Figure 1b). Like-
wise, when SMA 12b was administered to mice at concen-
trations of 01 lg or 10 lg per injection, the total number
of cells in BALF remained unaffected in such animals,
when compared to the group of untreated mice undergo-
ing HDM-induced airway hyper-responsiveness (Fig-
ure 1b). However, when 12b was administered at a
concentration of 1 lg per injection, the mean total num-
ber of cells decreased significantly compared to untreated
HDM mice (74 9 105 vs. 14 9 106 for total number of
BALF cells; P < 001; Figure 1b). The mean total cell
count values for 12b administered at 01 lg and 10 lg per
injection were 18 9 106 and 15 9 106, respectively. For
comparison, mice not exposed to HDM (‘control’) had a
mean total number of cells in the lungs of 10 9 105. Eosi-
nophils were not detected in the BALF of such mice,
whilst a mean number of 13 9 106 (89%) was detected in
HDM-treated mice (Figure 1c). However, this influx of
eosinophils was reduced with the 1 lg SMA/injection regi-
men in a similar manner to the decrease in total cells (Fig-
ure 1c,d). Indeed, whilst at the low and high
concentrations of 12b employed, the total numbers of
eosinophils were similar to those detected in the untreated
HDM group (16 9 106 (84%) and 12 9 106 (79%),
respectively; Figure 1b), at the effective middle
concentration of 1 lg of 12b per injection, this number
was significantly decreased to 56 9 105 (69%; P < 001).
Consistent with the total cell data (Figure 1b), SMA 11a
had no effect on the HDM-induced eosinophil influx
(Figure 1c,d).
By contrast to the eosinophil data, the absolute num-
bers of macrophages were found to increase in the BALF
of mice given SMA 12b at 10 lg per injection (Figure 1e),
whilst administration at 1 lg per injection induced an
increase in their levels as a proportion of BALF cells that
reached statistical significance when compared to the
untreated HDM group, with the percentage increasing
from 89 to 272 (Figure 1f). The mean proportion of
macrophages remained comparable to the HDM group for
12b employed at 01 lg (135%) and 10 lg/injection
(178%) groups. No changes in the number (Figure 1e) or
proportion (Figure 1f) of macrophages were observed
when administering SMA 11a. In spite of the observed
percentage increase following administration of 12b at
1 lg, flow cytometric analysis of the myeloid cells in the
lung tissue (results not shown) did not detect a significant
difference in either the M1 or M2 macrophage subsets or
the CD11b+ or CD103+ DC populations (11). The lym-
phocyte count was below 5 9 104 cells and remained
unchanged amongst the experimental groups, and neu-
trophils did not appear to be recruited into the lungs of
mice in any of the groups (data not shown).
To determine the effectiveness of SMA 12b at its active
concentration of 1 lg/injection at different time points in
preventing the pathology associated with HDM-induced
airway hypersensitivity, the SMA was administered either
prophylactically (at the sensitization stage only; 12b-1-S)
or therapeutically (at the challenges only; 12b-1-CH).
Total cell count in BALF of mice undergoing HDM-
induced airway hyper-responsiveness showed that SMA
12b, when administered prophylactically, was able to sup-
press the influx of cells into the lungs of mice significantly
compared to non-SMA-treated HDM mice (102 9 105 vs.
20 9 106 for total number of BALF cells; P < 005; Fig-
ure 2a). This decrease was consistent with a decrease in
eosinophils (from 19 9 106 cells to 51 9 105; P < 001;
Figure 2b). At the same time, an increase in total macro-
phage count was observed with SMA treatment (from
103 9 105 cells to 49 9 105; P < 005; Figure 2d). Pro-
portion wise, the data represented a decrease from 82% to
48% for eosinophils (P < 005; Figure 2c) and increase
from 145% to 49% of macrophages (P < 005; Figure 2e).
Similarly, when SMA 12b was administered therapeuti-
cally (at the challenges only), there was a decrease in
influx of cells into the lungs of HDM-treated mice (from
19 9 106 cells to 13 9 106; Figure 2a), although this was
less pronounced relative to prophylactic administration.
Nevertheless, this slight decrease in total cells in BALF
was consistent with a statistically significant decrease in
total eosinophils (from 19 9 106 cells to 11 9 106;
P < 005; Figure 2b). Proportion wise, this represented a
decrease from 82% to 68% (Figure 2c). Whilst no signifi-
cant effects of the SMA were observed with respect to the
number (Figure 2d), the proportion (Figure 2e) of macro-
phages was significantly increased from 145% to 285%
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when the SMA was only administered prior to HDM
challenges.
Effect of SMAs on lung pathology in the HDM model
At the cull day, lungs were collected from mice for
assessment of inflammation and pathology (Figure 3).
11a-1 and 12b-1 represent groups of mice treated with
either 11a or 12b at 1 lg per injection throughout the
model. 12b-1-S represents a group of HDM mice treated
with 12b prophylactically at the sensitization stage only.
H&E staining of mouse lung sections revealed
histopathological changes in mice exposed to HDM
extract. In particular, cellular infiltration and an increase
in airway thickness, which occurs due to an upsurge in
smooth muscle deposition around the airways, in combi-
nation with irregularity in the structure of the airways,
were observed in the HDM-treated mice, and this was
similar to what was observed in the 11a-1-treated group.
These changes were less obvious in the SMA 12b-1
group, as was mucus production, indicated by way of
PAS staining, within the airways. Also, when mice were
treated with 12b throughout the model, airway remod-
elling seemed to be suppressed. Furthermore, shedding
of cells was less visible resulting in more normal struc-
tures being observed in the airways. Similarly, when 12b
was administered prophylactically at the sensitization
only stage (12b-1-S group), lung pathology was reduced
in all aspects, to a level comparable to the lungs of
mice in the 12b-1 group. Likewise, when 12b was
administered just before challenge, we witnessed a reduc-
tion in the degree of lung inflammation (results not
shown).
We also stained sections with toluidine blue in an
attempt to detect mast cells as this cell type has been
previously shown to be a target of both ES-62 (5) and
SMAs (7). However, as discussed previously (7), it is not
always possible to find significant numbers of mast cells
in the lungs of mice employed in asthma models. Consis-
tent with this, we could not detect increased numbers in
HDM-treated mice as compared to control mice (results
not shown).
Figure 2 SMA 12b prevents influx of cells
into the lungs of mice undergoing HDM-
induced airway inflammation when
administered either prophylactically or
therapeutically. C57BL/6 mice undergoing
HDM-induced airway hyper-responsiveness
were treated with SMA 12b 1 h before either
sensitization (S) or challenges (CH) with
HDM extracts. (a) total cell count in BALF
collected at sacrifice. Influx of eosinophils
and macrophages is shown as both total
number of cells (b, d) and their proportion
(c, e) in BALF. Data are pulled from 3
independent experiments. Symbols on each
graph are representative of individual mice
in the indicated groups and where *P < 005
and **P < 001 P-value is indicated in
comparison with the HDM (none) control
and ###P < 0001 for control vs. HDM
mice.
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Effect of SMAs on cytokine gene expression in the
HDM model
To elucidate the mechanism of action of SMA 12b in the
HDM model of asthma, expression of a number of proin-
flammatory cytokines, in particular, IFN-c, IL-1b, IL-
17A, IL-4, IL-5 and IL-13, was examined. In addition, the
levels of Heme Oxygenase-1 (Hmox) that produces protec-
tive antioxidants (12) were analysed as imbalance in these
factors is commonly implicated in asthma (13). As
Figure 4 shows, the lungs of mice exposed to HDM
demonstrated a statistically significant increase in expres-
sion of IL-17A, IL-4, IL-5 and IL-13 relative to untreated
mice (all P < 001). No significant effects were observed
with respect to the other cytokines examined or Hmox in
the lungs. When measuring expression of these molecules
in the DLNs, only IL-5 and IL-13 were significantly
increased by HDM treatment (both P < 005; Figure S2).
Perhaps, consistent with this Th17/Th2 polarization,
HDM treatment tended to reduce IFN-c mRNA levels in
the lungs (Figure 4a). Treatment with SMA 12b through-
out significantly lowered the increased levels of IL-17A
mRNA in the lungs of mice undergoing airway hypersensi-
tivity (Figure 4c), and although the slight rise in IL-1b
mRNA levels resulting from HDM treatment did not
reach significance, a significant decrease was measured in
the lungs for the group of mice receiving 12b-1 (Fig-
ure 4b). These were the only significant reversals of
HDM-induced effects attributable to treatment with 12b-1
throughout the experiment in either the lungs (Figure 4)
or DLN (Figure S2). In addition, and consistent with its
lack of effect on HDM pathology, treatment with SMA
11a at 1 lg/injection throughout the model did not signifi-
cantly modulate the mRNA levels of any of the mediators
tested in lungs (Figure S3) and DLNs (Figure S4) as com-
pared to HDM-treated mice.
Levels of IL-1b and IL-17A mRNA were also decreased
in the lungs for the group treated with 12b only at sensiti-
zation, whereas these effects were not apparent for the
group of mice receiving 12b therapeutically at the HDM
challenges (Figure 4b,c). Like HDM treatment alone, 12b-
1 also tended to reduce the levels of IFN-c mRNA relative
to those pertaining in the control untreated mice and this
was also found for both 12b-1-S and 12b-1-CH where the
decreases reached statistical significance (Figure 4a). No
effects of 12b-1-S or 12b-1-CH treatments were detected
for any of the mediators in the DLNs at cull (Figure S2).
Effect of SMAs on the IgG1 antibody response in the
HDM model
To further investigate the protective effects of SMA 12b,
the levels of HDM-specific IgG1 immunoglobulins were
assessed. It was found however that there was no differ-
ence in specific antibody levels when mice hypersensitive
to HDM extracts received treatment with 12b-1 at any of
the time points – at the sensitization, throughout the
model or at the challenges only in comparison with mice
receiving HDM extract alone (Figure 5). Consistent with
this, flow cytometric analysis revealed that exposure to
12b-1 did not modulate the levels or phenotype of effector
(Marginal Zone, Follicular, Germinal Centre, Plasmablast
Figure 3 Histochemical staining of lung tissue from mice treated
with SMA 11a or 12b at different time points. Alveolar regions of
lung sections (7 lm) stained with H&E (a) and periodic acid-
Schiff (PAS; b) from C57BL/6 mice. Three different regions of
lungs were examined in mice from two independent experiments,
and representative figures are displayed. The control group was
not exposed to any treatment. The HDM group represents mice
exposed to HDM extracts in vehicle only. 11a-1 and 12b-1
represent groups of mice treated with either 11a or 12b at 1 lg per
injection throughout the model. 12b-1-S represents a group of
HDM mice treated with 12b prophylactically at the sensitization
stage only. Sections were examined using an Olympus BX41 light
microscope at 940 magnification and scale bars represent 200 lm.
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Figure 4 Effect of ES-62 SMA 12b on cytokine production in the lungs as measured by qRT-PCR. qRT-PCR analysis of IFN-c (a), IL-1b
(b), IL-17A (c), IL-4 (d), IL-5 (e), IL-13 (f) and Hmox (g) mRNA levels in the lungs of HDM mice treated with 12b throughout the model
(12b-1), either prophylactically at the sensitization only (12b-1-S) or therapeutically at the challenges only (12b-1-CH) stage. The data are
pooled from three independent experiments with values for samples being normalized to the reference reporter for GAPDH. Each symbol
represents the response from an individual mouse in the designated group and where *P < 005 indicates comparison between HDM
(none) and HDM-SMA-treated mice and ##P < 001 for control vs. HDM mice.
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or Plasma Cell) or putative regulatory IL-10+ B cells (14,
15) in the spleen (data not shown).
Testing of SMAs in the cockroach (CR) extract allergen
model
Mice were exposed to CR (15 or 50 lg/injection) during
sensitization, and challenge (Figure S1) and total and dif-
ferential cell counts in BALF determined. This analysis
revealed that exposure to CR at 50 lg per injection
resulted in significantly higher levels in the BALF of total
cells and also alveolar macrophages, eosinophils, neu-
trophils and lymphocytes (Figure 6 and results not shown;
see Figure S5 for flow cytometric gating strategy). Whilst
exposure to SMAs 11a and 12b employed at 1 lg per
injection did not have any significant effects on total or
alveolar macrophage, neutrophil or lymphocyte cell counts
found in mice treated with CR extract, the levels of eosi-
nophils found in the BALF of such treated animals were
not significantly different to those found in naive
untreated mice, indicating the SMAs were acting to sup-
press eosinophilic infiltration of the airways in this model
(Figure 6 and results not shown). A statistically significant
IgG1 antibody response was observed in 1 of 3 experi-
ments, but SMAs 11a and 12b had no effect on this (re-
sults not shown). However, when measuring cytokine
responses in DLNs, 11a significantly increased the IFN-c
(Figure 7a) and 12b inhibited the IL-4 (Figure 7b) recall
response to CR.
DISCUSSION
We have previously reported that ES-62 and its drug-like
SMAs 11a and 12b provide protection against OVA-
induced airway hyper-responsiveness in a mouse model (5–
7). Testing of helminths, their extracts or their defined
products on allergic airway inflammation has become
increasingly common over the past decade (reviewed in (1,
2, 4)) with the vast majority of the studies focusing on
OVA. Nevertheless, there are a few studies, which rather
than employ this model allergen, focus on molecules that
induce allergy in humans such as Derp1 from HDM (16)
and grass pollen allergen (17). The present work extends
these studies, employing both an HDM and a CR extract
to induce allergic airway responses in the lungs of mice.
SMAs 11a and 12b were initially tested in the HDM
model using three different doses of SMA per injection –
01, 1 and 10 lg – administered 1 h prior to each exposure
to HDM throughout the model. 11a had no effect on the
HDM-induced increase in cells in the BALF, but 12b was
effective in significantly reducing this when employed at
1 lg/injection. The reason underlying 12b only being effi-
cacious at the mid-dose level is unknown: we did not
observe such an effect in the OVA model (7) although we
have seen some evidence of it in collagen-induced arthritis
(CIA) where a log increase in the quantity of SMA
beyond 1 lg/injection reduces the protective effect (Pineda,
M.A., Harnett, M.M. & Harnett, W., unpublished data).
Parabolic dose–responses may not be unusual (18) as such
concentration/activity profiles are possible where a system
under investigation is not responding to a single-target/sin-
gle-drug intervention, which would typically exhibit a sim-
ple concentration dependence. In this case, we could
argue, for example, that SMA 12b has a high affinity tar-
get that is reflected in the initial concentration-dependent
increase of activity observed. However, if it also has a sec-
ondary low affinity target that signals the reverse of the
initial activity, this effect would be seen at higher concen-
tration. Alternatively, and perhaps more consistent with
our findings that ES-62/SMAs act to reset homeostatic
regulatory mechanisms, at higher concentration that satu-
rate responses from the high affinity target, there could be
compensating mechanisms within the cell that act to
restore the original state. This would obviate the need for
Figure 5 Measurement of HDM-specific IgG1 levels following
treatment with SMA 12b. Serum from HDM-hypersensitive mice
treated with 12b at different time points was obtained at the cull
day. Serum samples were diluted threefold, serially and
concentrations for HDM-specific IgG1 levels measured by
ELISA. The symbols on the graph show mean values, and SEM
of individual mouse IgG1 levels collated from two independent
experiments. #P < 005; ##P < 001; ###P < 0001 vs. control
(no HDM) at each dilution point.
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the SMA acting at a second lower affinity target. Three
concentration points are, of course, not enough to define
a profile but could be argued to be indicative of interact-
ing signalling mechanisms in the cells. Clearly, more
pharmacological analysis would have to be undertaken to
help resolve this issue. Likewise, the reason for the failure
of 11a to protect in the model is uncertain as such a result
was not observed in the OVA model (7). Nevertheless,
Figure 6 SMAs 11a and 12b inhibit influx of
eosinophils into the lungs of mice
undergoing CR-induced airway
inflammation. BALB/c mice undergoing
CR-induced airway hyper-responsiveness
(‘none’) were treated with SMAs 11a or 12b
1 h prior to each exposure to CR. (a) total
cell count in BALF collected at sacrifice.
Influx of alveolar macrophages (b:
Ly6C-Ly6G-CD3-CD19-CD11c+F4/80+),
eosinophils (c: SSChighSiglecF+) and
neutrophils (d: SSChighLy6G+) is shown as
total number of cells in BALF. Data are
pooled from 3 independent experiments.
Symbols on each graph are representative of
individual mice in the indicated groups. One
of the control mice was identified as an
outlier by the GraphPad Prism ROUT test
in all of these cell types and hence was
excluded from the statistical analyses where
*P < 005 and **P < 001 and the P-value is
indicated in comparison with the control (no
CR exposure) mice.
Figure 7 Effect of ES-62 SMAs on lymphocyte cytokine production. DLN cells (3 9 105 lymphocytes) were taken from control, CR- or
CR-SMA-treated animals and cultured ex vivo with medium alone or CR (50 lg) for 72 h. Cell culture supernatants were removed, and
IFN-c (a) and IL-4 levels measured by ELISA. The data presented are pooled from 3 independent experiments and *P < 005 and
***P < 0001 are for untreated CR-exposed mice (none) vs. SMA-treated CR-exposed mice and ###P < 0001 for control (no CR
exposure) vs. CR-exposed (none) mice.
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although the structures of 11a and 12b are based upon the
same conceptual design (10), it is already apparent that
they have somewhat different properties in vivo. For exam-
ple, although the two SMAs offer protection against
pathology in a model of oxazolone-induced skin inflam-
mation (19) and the MRL/Lpr model of systemic lupus
erythematosus (20) in both cases, SMA 11a is the more
effective. Thus, we may simply be observing differences in
the efficacy of the SMAs commensurate with differences
in their structures (see Figure 1 for structures) the impor-
tance of which needs to be unravelled in relation to the
different models. Of note, SMA 12b was also found to be
effective when administered only before sensitization or
only before challenge indicating that it has both prophy-
lactic and therapeutic potential with respect to employ-
ment as a drug.
Differential cell analysis revealed that SMA 12b targeted
eosinophil infiltration, and this was the case regardless of
when the SMA was administered. Previously, we had
shown that 12b inhibited eosinophil infiltration in the pro-
phylactic version of the OVA model, but the neutrophil
was found to be the target cell in a therapeutic model (7).
However, no neutrophil infiltration of the lungs was
observed in the present study, and hence, anti-neutrophil
effects could not be measured. Further analysis revealed
that 12b but not 11a had additional effects on the airways
of animals undergoing HDM-induced allergy including
reducing mucus production and preventing airway thicken-
ing and remodelling. Such observations increase the likeli-
hood that 12b may have both prophylactic and therapeutic
potential as a treatment for allergic airway disease, even
after the onset of lung pathology associated with chronic
asthma and hence may have application to each of mild,
moderate and severe asthma (the last being particularly
difficult to treat). In addition, 12b (and 11a) is a prototype
compound suitable for proof-of-concept experiments such
as these: the structures have not as yet been optimized
and so it can be anticipated that both potency and selec-
tivity can be improved in development.
Induction of allergy in the lungs via HDM resulted in an
increase in mRNA for IL-4, IL-5, IL-13 and IL-17.
Although 12b when administered throughout the model
had no effect on the Th2 cytokines (the lack of effect on IL-
4 may also help explain the lack of effect on specific IgG1
antibody levels), it reduced expression of IL-17, a cytokine
reported as contributing to eosinophil activation (21). Previ-
ously, we have observed that both ES-62 (6) and 12b (7)
reduce IL-17 mRNA levels in the lungs when employing the
prophylactic OVA model although on this occasion, IL-4
was also inhibited (the other Th2 cytokines were not mea-
sured). The cell type responsible for the IL-17 production
that is being targeted by 12b in the HDM model remains to
be established, but it is known from our studies on CIA that
the parent molecule ES-62 can inhibit IL-17 production in a
number of ways including direct and indirect (via APC)
effects on IL-17-producing cells such as Th17 cells and cd T
cells (22). Of note, 12b does not appear to directly target IL-
17 responses in CIA, focusing instead on IL-1b (23). How-
ever, consistent with this latter result, although not signifi-
cantly altered by HDM-induced allergy, IL-1b mRNA
levels are reduced by 12b treatment in this model. IFN-c
levels are dampened in a similar manner although these
tend to be unaltered by 12b (7) and indeed elevated by ES-
62 (6), in the OVA model. Thus, the protective effects associ-
ated with reversal of Th polarity observed previously in the
OVA model (6, 7) do not appear to pertain here. In the
HDM model, effects on converging IL-1b and IL-17 sig-
nalling in lung pathology may thus be more important. Cer-
tainly, the latter cytokine has been reported to play a key
role in the HDM model (24), which makes the failure of
SMA 11a – an SMA known to target IL-17 responses (7,
10) – somewhat surprising.
Regarding the effect of the SMAs on other cell types
known to be targets, as with neutrophils, we could not
find increased numbers of mast cells in the lungs of
HDM-exposed mice, and hence, it appears that this cell
type does not represent an obvious component of the
inflammatory response in this model. Consistent with
this, we did not find any increase in HDM-specific serum
IgE levels (results not shown). We also considered the B
cell as a target because it has emerged from our work on
mouse models of rheumatoid arthritis (15), systemic lupus
erythematosus (14) and more recently a chronic OVA-
based asthma model (25) that protection afforded by ES-
62 involves resetting the homeostatic balance between reg-
ulatory (Breg) and effector B cells. Our findings relating
to Bregs were disappointing however as we found 12b to
only induce small insignificant increases in splenic IL-10+
B cells in HDM mice at cull (d14, from about 15 to
17%). Nevertheless, a number of the parasitic worm stud-
ies have now demonstrated that the protective efficacy of
such putative Breg populations depends on their localiza-
tion (reviewed in (25)) indicating that the spleen,
although the organ traditionally investigated for the
induction and function of such cells, may not have been
the best site of investigation. Also of note, our data in
the chronic OVA model have revealed the protective
induction of MZ-like Bregs by ES-62 and 12b to be acute
and dynamic raising the possibility that we may have
missed the peak of any Breg induction. This may addi-
tionally suggest that if SMAs do induce Bregs in the
HDM model, they are likely to be using this same acute
mechanism of action at both sensitization and challenge.
Certainly, this would be consistent with what appears to
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be a somewhat acute inhibition of inflammatory
responses rather than a repolarization of Th responses, as
would be reflected by modulation of the levels of cytoki-
nes, such as IL-4. In any case, we plan to further explore
these matters at a later date.
Finally, in contrast to the HDM model, both SMAs 11a
and 12b exhibited some protective effects on CR-induced
allergic airway inflammation with both, as in the OVA
model (7), tending to reduce eosinophilic infiltration of
the lungs. Although neutrophilic infiltration was induced
by CR, this was not modified by either 11a or 12b, unlike
the situation in the OVA model where prophylactic expo-
sure to 12b also inhibited this inflammatory response (7).
However, we did observe effects on IFN-c (increased) and
IL-4 (decreased) DLN recall cytokine responses, which
may be consistent with the suppression of eosinophil
responses, in that IL-4 is known to increase the number of
this cell type in the airways and lungs of mice in an anti-
gen-dependent manner (26), as well as with the anti-allergy
effects noted with ES-62 and the SMAs in the OVA model
(6, 7). Also, when we then moved on to employ the CRE
model, the published regimens most resembled our
prophylactic OVA model where SMAs had been success-
fully administered subcutaneously (7). However, although
evidence of protection has been obtained in both models
in the present study, obviously, without exploring all
routes of administration in all models, we cannot know
which are most effective. Thus, further experimentation
may be warranted here although this will probably await
the development of second generation SMAs based
around the structures of 11a and 12b. Certainly, overall,
exploitation of the HDM and CR models in addition to
the OVA model not only allows us to test ‘clinically rele-
vant’ allergens, but increases our knowledge of the selec-
tivity in activity of the SMAs in different inflammatory
contexts; importantly, in the case of 11a, it has also shown
that what works with a model allergen may not necessarily
afford protection against all members of the ‘real thing’.
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Figure S1. Schematic of HDM and
CR models of airway hyper-respon-
siveness. For the HDM model,
C57BL/6 animals were treated intra-
nasally with SMAs 11a or 12b (10, 1
and 01 lg/dose) 1 h prior to admin-
istration of HDM extract (1 or
10 lg/dose). The cockroach extract
model utilized BALB/c animals that
were treated with SMAs 11a or 12b
(1 lg/dose) subcutaneously prior to
each intranasal administration of CR
(15 or 50 lg/dose).
Figure S2. Effect of ES-62 SMA
12b on cytokine production in the
draining lymph nodes as measured
by qRT-PCR. qRT-PCR analysis of
IFN-c (a), IL-1b (b), IL-17A (c), IL-
4 (d), IL-5 (e), IL-13 (f) and Hmox
(g) mRNA levels in the lungs of
HDM mice treated with 12b either
throughout the model (12b-1), pro-
phylactically at the sensitization only
(12b-1-S) or therapeutically at the
challenges only (12b-1-CH) stage.
The data are pooled from three
independent experiments with values
for sample being normalized to the
reference reporter for GAPDH. Each
symbol represents the response from
individual mice in the designated
group and where ##P < 005 for
untreated (“Control”) vs. HDM-trea-
ted (“None”) mice.
Figure S3. Effect of ES-62 SMA
11a on cytokine production in the
lungs as measured by qRT-PCR.
qRT-PCR analysis of IFN-c (a), IL-
1b (b), IL-17A (c), IL-4 (d), IL-5 (e),
IL-13 (f) and Hmox (g) mRNA levels
in the lungs of HDM mice untreated
(“None”) or treated with 1 lg injec-
tions of 11a (“11a-1”) throughout the
model. The data are from a single
experiment with values for samples
being normalized to the reference
reporter for GAPDH. Each symbol
represents the response from individ-
ual mice in the designated group.
Figure S4. Effect of ES-62 SMA
11a on cytokine production in the
draining lymph nodes as measured
by qRT-PCR. qRT-PCR analysis of
IFN-c (a), IL-1b (b), IL-17A (c), IL-
4 (d), IL-5 (e), IL-13 (f) and Hmox
(g) mRNA levels in the lungs of
HDM mice untreated (“None”) or
treated with 1 lg injections of 11a
(“11a-1”) throughout the model. The
data are from a single experiment
with values for samples being nor-
malized to the reference reporter for
GAPDH. Each symbol represents the
response from individual mice in the
designated group.
Figure S5. Representative flow cyto-
metric gating strategy for the CR
extract model. For the flow cytometric
phenotypic analysis, the cells of interest
and exclusion of doublets were deter-
mined by the forward and side scatter
parameters of the cellular populations
(a, b). Siglec F was used to identify
Eosinophils (c: SSChighSiglecF+), while
a separate staining panel was used to
identify Neutrophils (d: SSChigh-
Ly6G+). The Ly6G- population in D
was further discriminated on the basis
of their Ly6C expression (e) and follow-
ing selection of the Ly6C-Ly6G
CD3CD19 cells, the subsequent use
of F4/80 and CD11c allowed the identi-
fication of Alveolar Macrophages (f:
Ly6CLy6GCD3CD19CD11c+F4/
80+).
© 2016 The Authors. Parasite Immunology Published by John Wiley & Sons Ltd., Parasite Immunology, 38, 340–351 351
Volume 38, Number 6, June 2016 Testing ES-62 analogues in allergy
